kabutan

Daito Pharmaceutical Co.,Ltd.(4577) Summary

4577
TSE Prime
Daito Pharmaceutical Co.,Ltd.
1,260
JPY
-5
(-0.40%)
Apr 28, 3:30 pm JST
7.91
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
14.5
PBR
0.70
Yield
3.17%
Margin Trading Ratio
57.10
Stock Price
Apr 28, 2026
Opening Apr 28, 9:00 am
1,261 JPY 7.91 USD
Previous Close Apr 27
1,265 JPY 7.93 USD
High Apr 28, 9:00 am
1,263 JPY 7.92 USD
Low Apr 28, 9:21 am
1,246 JPY 7.81 USD
Volume
82,900
Trading Value
0.10B JPY 0.65M USD
VWAP
1255.79 JPY 7.89 USD
Minimum Trading Value
126,000 JPY 791 USD
Market Cap
0.04T JPY 0.24B USD
Number of Trades
233
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
Mid
1-Year Average
273
1-Year High Jul 14, 2025
1,532
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 51,000 35,900 0.70
Apr 17, 2026 77,500 30,800 0.40
Apr 10, 2026 74,900 43,400 0.58
Apr 3, 2026 72,500 34,500 0.48
Mar 27, 2026 100,400 41,500 0.41
Company Profile
Daito Pharmaceutical Co., Ltd. specializes in the manufacturing of active pharmaceutical ingredients (APIs) and contract manufacturing of pharmaceutical products, primarily serving generic drug manufacturers.
Sector
Pharmaceuticals
Daito Pharmaceutical Co., Ltd. focuses on the manufacturing and sales of APIs and pharmaceutical products, as well as contract manufacturing and distribution, while also engaging in health food sales. In the API sector, the company manufactures and sells both in-house developed products and those co-developed with partners, maintaining extensive business relationships with domestic and international pharmaceutical companies. The company has a particularly strong track record in supplying APIs, mainly self-developed, to generic drug manufacturers. In pharmaceutical production, Daito actively engages in contract manufacturing of brand-name drugs for major domestic pharmaceutical companies, while also developing and manufacturing generic drugs. With its high-quality control capabilities and production facilities capable of handling various dosage forms, the company is able to undertake manufacturing contracts from major innovative drug companies. Daito's integrated manufacturing system, covering everything from APIs to finished pharmaceutical products, serves as a significant competitive advantage.